- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Molly Burich: How to Improve Biosimilar Uptake
Molly Burich, MS, head of public policy at Boehringer Ingelheim, discusses several tactics that would help increase biosimilar uptake in the United States and get around current obstacles during the World Biosimilar Congress USA 2020 at the Festival of Biologics USA in San Diego, California.
Molly Burich, MS, is the head of public policy at Boehringer Ingelheim.
Transcript:
With all the obstacles to biosimilar competition, where is the work around to other solutions?
There's no question that there's barriers to the uptake of biosimilars. We have reimbursement systems that can have a tendency to incent a higher cost product. So, what we need to see are some efforts at the federal and payer level that will allow some of those misaligned incentives to be removed or adjusted to get the biosimilar market moving. Some of those ideas can include things like shared savings, where you give physicians and patients an opportunity to share some of the savings that are generated from using lower cost products. The administration has the ability in their authority now to implement a shared savings program. We've also seen some congressional activity around increasing ASP [average sales price] add-on for physicians, zero-dollar cost share for patients, Part D Star ratings measures around biosimilars. All of those things are really important to help get the market moving and stimulate the biosimilar market so that we not only have better uptake now, but that we have a long-term robust and sustainable market where we're truly driving down costs.
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
February 19th 2023COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
